•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

OXYNTOMODULINDiabetes

AUR A KINASE INHIBITOR Cancer

MIRIKIZUMABCrohn’s Disease

BARICITINIB Systemic Lupus Erythematosus

MEVIDALENSymptomatic LBD

TIRZEPATIDEDiabetes

EMPAGLIFLOZIN*Heart Failure pEF

TANEZUMAB*Osteoarthritis Pain

SOLANEZUMABPreclinical AD

MIRIKIZUMABUlcerative Colitis

BTLA MAB AGONISTImmunology

CD200R MAB AGONIST Immunology

O-GLCNACASE INHAlzheimer’s

GGG TRI-AGONISTDiabetes

CONNECTED CARE PREFILLED INSULIN PEN Diabetes

GLP-1R NPADiabetes

SERDCancer

TIRZEPATIDEObesity

LEBRIKIZUMABAtopic Dermatitis

SELPERCATINIB1L Med Thyroid Cancer

GIP/GLP COAGONIST PEPTIDE Diabetes

N3PG Ab MAB Alzheimer’s

NRG4 AGONISTHeart Failure

KHK INHIBITORDiabetes / NASH

LP(a) INHIBITORCVD

IDH1 INHIBITOR Cancer

EMPAGLIFLOZIN*Heart Failure rEF

ABEMACICLIBAdjuvant Breast Cancer

TRPA1 ANTAGONIST Pain

GRN GENE THERAPYFrontotemporal Dementia

GBA1 GENE THERAPYParkinson’s Disease

ANGPTL3 siRNA CVD

GIPR AGONIST LA Diabetes

IL-17A SMALL MOLINHIBITOR Immunology

KHK INHIBITOR IIDiabetes / NASH

P2X7 INHIBITORPain

NOT DISCLOSEDDiabetes

PYY ANALOGDiabetes

RIPK1 INHIBITORImmunology

GIP/GLP COAGONIST PEPTIDE II Diabetes

ANGPTL3/8 MABCVD

RELAXIN-LAHeart Failure

BASAL INSULIN-FCDiabetes

AUTOMATED INSULIN DELIVERY SYS Diabetes

CXCR1/2L MABHidradenitis Suppurativa

EPIREG/TGFa MABChronic Pain

IL-2 CONJUGATESystemic Lupus Erythematosus

PACAP38 MABMigraine

SSTR4 AGONISTPain

TIRZEPATIDENASH

ABEMACICLIBProstate Cancer

ZAGOTENEMAB Alzheimer’s

DONANEMABEarly Alzheimer’s

EMPAGLIFLOZIN*Post MI

MIRIKIZUMABPsoriasis

BARICITINIBAlopecia Areata

TANEZUMAB*Cancer Pain

TIRZEPATIDECV Outcomes

SELPERCATINIB1L NSCLC

EMPAGLIFLOZIN*Chronic Kidney Disease

VIR-7831 +BAMLANIVIMAB COVID-19

PIRTOBRUTINIB(LOXO-305)B-Cell Malignancies

PIRTOBRUTINIB(LOXO-305)R/R CLL monotherapy

CD73 INHIBITOR Cancer

LY-CoV1404 MABCOVID-19

NME

NILEX

*

MOVEMENT SINCEJanuary 26, 2021

ADDITION or

MILESTONE ACHIEVED

REMOVAL

Commercial

Collaboration

^ Emergency Use Authorization has been granted in

the US and other countries

IL-2 CONJUGATEUlcerative Colitis

PD-1 MAB AGONISTRheumatoid Arthritis

BARICITINIB^COVID-19

BAMLANIVIMAB & ETESEVIMAB^COVID-19

New since last update

✓✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓✓

✓

✓

✓✓

✓

▪

▪

▪

▪

▪

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

>

>

>

>

>

<

<

>

>